<DOC>
	<DOCNO>NCT01529827</DOCNO>
	<brief_summary>This phase II trial study well give fludarabine phosphate , melphalan , low-dose total-body irradiation ( TBI ) follow donor peripheral blood stem cell transplant ( PBSCT ) work treat patient hematologic malignancy . Giving chemotherapy drug fludarabine phosphate melphalan , low-dose TBI donor PBSCT help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving tacrolimus , mycophenolate mofetil ( MMF ) , methotrexate transplant may stop happen</brief_summary>
	<brief_title>Fludarabine Phosphate , Melphalan , Low-Dose Total-Body Irradiation Followed Donor Peripheral Blood Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine transplant relate mortality ( TRM ) reduced-intensity transplantation ( RIT ) combination , fludarabine ( fludarabine phosphate ) , melphalan , TBI patient population usually eligible full myeloablative allogeneic hematopoietic stem cell transplantation ( HSCT ) . SECONDARY OBJECTIVES : I . To evaluate clinical response , progression free survival ( PFS ) one year , engraftment rate , graft-versus-host disease ( GvHD ) incidence propose RIT regimen across variety hematological condition . II . Correlative study include chimerism analysis molecular analysis evaluation immune reconstitution cytomegalovirus ( CMV ) dextramer analysis use flow cytometry . OUTLINE : PREPARATIVE REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -5 -2 melphalan IV 30 minute day -2 . Patients undergo low-dose TBI twice daily ( BID ) day -1 . TRANSPLANTATION : Patients undergo allogeneic PBSCT day 0 . GvHD PROPHYLAXIS : Patients receive tacrolimus IV orally ( PO ) BID day -1 100 taper 4-6 month , MMF PO IV every 6-8 hour day -1 60 , methotrexate IV 15-30 minute day 1 , 3 , 6 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Lipomatosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Diagnosis histology document hematologic malignancy marrow disorder BONE MARROW FAILURE DISORDERS : Acquired bone marrow failure disorder include aplastic anemia , paroxysmal nocturnal hemoglobinuria ( PNH ) * Primary allogeneic HSCT appropriate select patient severe aplastic anemia ; however , patient aplastic anemia must fail least one cycle standard immunosuppressive therapy calcineurin inhibitor plus antithymocyte globulin ( ATG ) fully match donor available * Patients PNH eligible myeloablative HSCT Hereditary bone marrow failure disorder include DiamondBlackfan Anemia , ShwachmanDiamond Syndrome , Kostmann Syndrome , congenital Amegakaryocytic Thrombocytopenia ; Fanconi Anemia relate chromosomal breakage syndrome , Dyskeratosis Congenital exclude study die poor deoxyribonucleic acid ( DNA ) repair capacity * Fanconi anemia relate chromosomal breakage syndrome : positive chromosome breakage analysis use diepoxybutane ( DEB ) mitomycin C applicable * Dyskeratosis Congenita : diagnosis support use either telomerase RNA component ( TERC ) gene mutation autosomal dominant Dyskeratosis Congenita Xlinked DKC1 gene mutation Other nonmalignant hematologic immunologic disorder require transplantation * Quantitative qualitative congenital platelet disorder ( include limit congenital amegakaryocytopenia , absentradii syndrome , Glanzmann 's thrombasthenia ) * Quantitative qualitative congenital neutrophil disorder ( include limit chronic granulomatous disease , congenital neutropenia ) *Congenital primary immunodeficiency syndrome , WiskottAldrich syndrome , CD40 ligand deficiency , Tcell deficiency ) ACUTE LEUKEMIAS : Subjects must ineligible unable receive conventional myeloablative transplantation Resistant recurrent disease least one standard combination chemotherapy OR first remission patient high risk relapse * Acute myeloid leukemia ( AML ) antecedent myelodysplastic syndrome , secondary AML , high risk cytogenetic abnormality normal cytogenetics highrisk molecular mutation ( e.g. , fmslike tyrosine kinase3internal tandem duplication [ Flt3ITD ] mutation ) * Acute lymphocytic leukemia ( ALL ) high standard risk ALL CHRONIC MYELOID LEUKEMIA ( CML ) : Chronic phase ( intolerant unresponsive imatinib and/or tyrosine kinase inhibitor ) , second chronic phase accelerate phase ineligible conventional myeloablative transplantation MYELOPROLIFERATIVE AND MYELODYSPLASTIC SYNDROME ( MDS ) : Myelofibrosis ( with/without splenectomy ) intermediate high risk feature Advanced polycythemia vera respond standard therapy MDS low International Prognostic Scoring System ( IPSS ) score intermediate ( Int ) 2 high MDS low IPSS score Int1 less severe clinical feature severe neutropenia thrombocytopenia high risk chromosome abnormality monosomy 7 Secondary MDS IPSS score Chronic myelomonocytic leukemia LYMPHOPROLIFERATIVE DISEASE : Chronic lymphocytic leukemia ( CLL ) , lowgrade nonHodgkin lymphoma ( NHL ) ( recurrent persistent ) fludarabine refractory le 6 month duration complete remission ( CR ) course conventional therapy Multiple myeloma ( progressive disease autologous stem cell transplant , tandem allogeneic transplant prior autologous stem cell transplant ) Waldenstrom 's macroglobulinemia ( fail one standard regimen ) High grade NHL diffuse large Bcell lymphoma ( DLBCL ) Not eligible conventional myeloablative HSCT OR fail autologous HSCT First remission lymphoblastic lymphoma , small , noncleaved cell lymphoma mantle cell lymphoma HODGKIN LYMPHOMA : Received failed frontline therapy Failed eligible autologous transplantation DONOR : Permissible human leukocyte antigen ( HLA ) matching : related donor single antigen mismatch HLA A , B , DRB1 ; unrelated donor single antigen mismatch HLA A , B , C , +/ additional single allele level mismatch A , B , V DRB1 Minimum goal peripheral blood stem cell ( PBSC ) dose 2 x 10^6 CD34+ cells/kg recipient weight ; minimum goal marrow dose 1 x 10^8 nucleated cells/kg recipient weight No serious uncontrolled psychiatric illness No concomitant active malignancy would expect require chemotherapy within 3 year transplant ( nonmelanoma skin cancer ) Nonpregnant nonnursing woman ; ( woman men reproductive potential agree use effective mean birth control ) Patients fail prior autologous allogeneic transplant eligible ; however , least 90 day must elapse start reduce intensity condition regimen last transplant patient prior autologous myeloablative allogeneic bone marrow transplant ( BMT ) At least 2 week since prior chemotherapy , radiation treatment and/or surgery Informed consent DONOR : Compatibility four informative HLA locus : A , B , C DRB1 important reduce risk GVHD successful transplant outcome ; A , B , C DRB1 loci comprise 8 possible allele ( haplotype inherit parent ) ; one additional locus , HLADQ , also type ascertain haplotype assist search compatible donor ; however mismatch DQ show associated adverse outcome ; high resolution molecular typing ( allele level ) standard care unrelated donor search allow great refinement search strategy DONOR : Matched relate donor : single antigen mismatch A , B , DR transplant family member associate high risk GVHD similar overall survival compare full identity 3 region ; relate donor/recipient pair must match 5 6 HLA antigen ( A , B , DRB1 ) DONOR : Unrelated Donor : When evaluate patient unrelated donor transplant , high degree matching , low risk GvHD ; A , B , C , DRB1 DQB1 locus , comprise 10 possible antigen ( allele ) , type unrelated transplant ; give high risk TRM mismatch transplant , RIT often best way mitigate risk ; data National Marrow Donor Program make possible estimate risk donorrecipient HLA mismatch allele antigen level ; high risk HLAmismatching must balance clinical urgency patient 's risk transplant team ; time , antigen level mismatch DQB1 affect outcome use matching purpose donor selection ; thus , match require HLA A , B , C DRB1 ( 8 locus ) ; protocol , single antigen mismatch HLA A , B , C , without additional single allele level mismatch may participate protocol voluntary unrelated donor ( blood marrow ) DONOR : Donor must healthy nonreactive test result infectious disease assay require state federal regulation ; donor screen seropositive hepatitis an/or syphilis must clear infectious disease consultation DONOR : Donor must uncontrolled cardiopulmonary , renal , endocrine , hepatic psychiatric disease render donation unsafe DONOR : The donor ( parent minor ) must give informed consent peripheral blood stem cell collection bone marrow collection DONOR : Syngeneic donor eligible DONOR : Donors poor peripheral venous access , may require central venous line placement stem cell apheresis Uncontrolled central nervous system ( CNS ) disease ( hematologic malignancy ) Karnofsky ( adult ) Lansky ( = &lt; 16 year ) performance status &lt; 50 % Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 40 % predict , correct hemoglobin and/or alveolar ventilation Left ventricular ejection fraction &lt; 40 % Bilirubin &gt; = 3 X upper limit normal Liver alkaline phosphatase &gt; = 3 x upper limit normal Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvate transaminase ( SGPT ) &gt; = 3 x upper limit normal Child 's class B C liver failure Calculated creatinine clearance &lt; 40 cc/min modify CockroftGault formula adult Schwartz formula pediatrics Patients receive maximally allow dos ( give 2 Gy fractionation , equivalent ) previous radiation therapy various organ follow : * Mediastinum : adult 40 , pediatric ( = &lt; 18 yr ) 21 * Heart : adult 36 , pediatric 26 * Whole lung ( ) : adult 12 , pediatric 10 * Small bowel : adult 46 , pediatric 40 * Kidneys : adult 12 , pediatric 10 * Whole liver : adult 20 , pediatric 20 * Spinal cord : adult 36 , pediatric 36 * Whole Brain : adult 30 , pediatric 30 Patients previously receive high allow dose radiation small lung , liver , brain volume , evaluate radiation oncologist determine patient eligible study Uncontrolled diabetes mellitus , cardiovascular disease , active serious infection condition , opinion treat physician , would make protocol unreasonably hazardous patient Human immunodeficiency virus ( HIV ) positive Patients opinion treat physician unlikely comply restriction allogeneic stem cell transplantation base formal psychosocial screen Female childbearing potential positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>